Skip to main content

Market Overview

Barclays Raises Valeant Pharmaceuticals' Price Target

Share:

Barclays raised its price target on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) from $149 to $179 Friday and maintained a Buy rating.

Analyst David Steinberg noted that the “surprisingly strong rev guidance (implied 14-15 percent Y/Y growth) is ~$150M ahead of the co’s prior 3Q14 update and should be driven in part by higher than expected rev from key new product launches.”

“The outstanding launch of Jublia (annualizing at $200M+ just 6 mos post launch), the breadth of the ophthalmic business (led by Ultra), and the new topical acne drug Onexton are all expected to be major contributors. Further, ~$200M in incremental sales are expected from new acquisitions (Marathon, Nicox, and Croma). In our view, the strength of the company’s underlying business continues to be underappreciated as ~$500M is expected from new products in FY15 – which constitutes pure organic growth,” according to Steinberg.

The analyst report was also positive due to “an acquisition-light FY14, the co’s leverage ratio is now just 3.5x, which should offer more flexibility for VRX to pursue its acquisition strategy.”

The price target of $179 was based on 14.8x the firm’s FY16 EPS figure of $12.12.

CRT also had positive comments for Valeant Pharmaceuticals on Friday.

Valeant Pharmaceuticals closed Friday at $153.58, down 0.34 percent.

Latest Ratings for VRX

DateFirmActionFromTo
Jun 2018TD SecuritiesDowngradesBuyHold
Jun 2018BarclaysUpgradesEqual-WeightOverweight
May 2018MizuhoUpgradesNeutralBuy

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

 

Related Articles (VRX)

View Comments and Join the Discussion!

Posted-In: Barclays CRT David SteinbergAnalyst Color Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
CMRXHC Wainwright & Co.Maintains18.0
PZZAStephens & Co.Maintains115.0
SIMONeedhamMaintains100.0
STAACanaccord GenuityMaintains150.0
DGIICanaccord GenuityMaintains25.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com